Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • In Brief
  • Published:

Sequencing

CpG islands and 5-hydroxymethylcytosine

Nature Reviews Cancer volume 12, page 374 (2012)Cite this article

Subjects

The mutation of the TET enzymes has been implicated in the development of leukaemia. These convert 5-methylcytosine to 5-hydroxymethylcytosine (5hmC). A new method, oxidative bisulphite sequencing, along with the established method of bisulphite sequencing, can quantitatively map the presence of 5hmC at single nucleotide resolution. High levels of 5hmC were present at CpG islands associated with transcriptional regulators and in LINE1 elements, and this supports the concept that 5hmC is present at DNA sites that are particularly epigenetically plastic.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to the full article PDF.

USD 39.95

Prices may be subject to local taxes which are calculated during checkout

ORIGINAL RESEARCH PAPER

  1. Booth, M. J. et al. Quantitative sequencing of 5-methylcytosine and 5-hydroxymethylcytosine at single-base resolution. Science 26 Apr 2012 (doi:10.1126/science.1220671)

Download references

Authors
  1. Nicola McCarthy
    View author publications

    Search author on:PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

McCarthy, N. CpG islands and 5-hydroxymethylcytosine. Nat Rev Cancer 12, 374 (2012). https://doi.org/10.1038/nrc3293

Download citation

  • Published:

  • Issue date:

  • DOI: https://doi.org/10.1038/nrc3293

Search

Advanced search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research